Unsolved:Persistent aura without infarction
| Persistent aura without infarction | |
|---|---|
| Specialty | Neurology, Neuro-ophthalmology |
| Symptoms | Prolonged aura in vision, Visual snow |
| Duration | Long-term |
| Causes | Unknown |
| Risk factors | Migraine sufferer |
| Differential diagnosis | Scintillating scotoma, Visual snow |
Persistent aura without infarction (PAWOI) is a rare and seemingly benign[1] condition, first described in case reports in 1982 as "prolonged/persistent migraine aura status",[2] and in 2000 as "migraine aura status",[3][4] that is not yet fully understood. PAWOI is said to possibly be a factor involved in a variety of neurological symptoms, including visual snow, loss of vision, increased afterimages, tinnitus, and others. The pathogenesis of PAWOI is unknown. It is not clear which medical examinations are useful in diagnosing PAWOI. At present, PAWOI is usually diagnosed solely based on the patient's current and past symptoms. It is possible that an "overactive brain" or a chemical imbalance underlies the disorder. Various medications have been tried as treatment, notably acetazolamide,[3] valproate,[4] lamotrigine,[1] topiramate, and furosemide.[5]
References
- ↑ 1.0 1.1 Chen, WT; Fuh, JL; Lu, SR; Wang, SJ (September 2001). "Persistent migrainous visual phenomena might be responsive to lamotrigine". Headache 41 (8): 823–5. doi:10.1046/j.1526-4610.2001.01150.x. PMID 11576209.
- ↑ Haas, David C. (February 1982). "Prolonged migraine aura status". Annals of Neurology 11 (2): 197–9. doi:10.1002/ana.410110217. PMID 7073253.
- ↑ 3.0 3.1 Haan, J; Sluis, P; Sluis, LH; Ferrari, MD (28 November 2000). "Acetazolamide treatment for migraine aura status". Neurology 55 (10): 1588–9. doi:10.1212/WNL.55.10.1588. PMID 11094126.
- ↑ 4.0 4.1 Rothrock, JF (January 1997). "Successful treatment of persistent migraine aura with divalproex sodium". Neurology 48 (1): 261–2. doi:10.1212/WNL.48.1.261. PMID 9008529.
- ↑ Rozen, Todd D. (12 September 2000). "Treatment of a prolonged migrainous aura with intravenous furosemide". Neurology 55 (5): 732–3. doi:10.1212/WNL.55.5.732. PMID 10980751.
 |  |
